Shionogi starts global Phase II clinical trial of redasemtide

Shionogi has started a global late Phase II clinical trial of redasemtide for the treatment of patients with acute ischemic stroke.

Redasemtide is a regeneration inducing medicine introduced by StemRIM, an Osaka-based drug discovery research and development-oriented biotech company.